RENALYTIX PLC SPON ADS EACH REP 50 ORD (POST SPLIT)(RNLXD.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
RENALYTIX PLC SPON ADS EACH REP 50 ORD (POST SPLIT)
RNLXD.US
62.65 B
RNLXD.USMarket value -Rank by Market Cap -/-

Financial Score

22/01/2026 Update
C
Health Care TechnologyIndustry
Industry Ranking22/47
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE255.00%A
    • Profit Margin-680.00%E
    • Gross Margin40.00%B
  • Growth ScoreB
    • Revenue YoY30.43%A
    • Net Profit YoY55.16%B
    • Total Assets YoY-14.08%E
    • Net Assets YoY22.22%A
  • Cash ScoreB
    • Cash Flow Margin-14.71%D
    • OCF YoY30.43%A
  • Operating ScoreC
    • Turnover0.45C
  • Debt ScoreE
    • Gearing Ratio214.75%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Renalytix AI Reports Strong Growth and Strategic Expansion

    Renalytix AI Plc reports strong growth in its 2025 financial year, with a 30% revenue increase and a 37% rise in commercial testing volumes. The company reduced administrative expenses by over 40% and decreased EBITDA loss by 54%. Successful capital raises totaled £18.5 million. Strategic partnerships and Medicare reimbursement boosted growth. Future plans include expanding KidneyIntelX technology integration, insurance coverage, and international market opportunities.

    Tip Ranks·
    US
    RNLXY
    0.00%
    US
    RNLXD
    0.00%
    Tip Ranks·
    US
    RNLXY
    0.00%
    US
    RNLXD
    0.00%

    REG - Renalytix PLC - Publication of Annual Report & Notice of AGM

    Renalytix PLC has published its Annual Report for the year ended June 30, 2025, and the Notice of the 2025 Annual General Meeting (AGM). The AGM is scheduled for December 9, 2025, in London. Shareholders can access the Annual Report on the company's website and must register to attend the AGM. Renalytix is known for its FDA-approved kidney disease prognostic test, kidneyintelX.dkd, which is now commercially available in the U.S. and has received Medicare reimbursement.

    London Stock Exchange·
    US
    RNLXY
    0.00%
    US
    RNLXD
    0.00%
    London Stock Exchange·
    US
    RNLXY
    0.00%
    US
    RNLXD
    0.00%

    REG - Renalytix PLC - Holding(s) in Company

    Renalytix PLC announced a major holding notification from UBS Group AG, which acquired 5.200990% of voting rights, totaling 21,083,181 shares. This acquisition was reported on October 10, 2025, after the threshold was crossed on October 9, 2025. The previous holding was 8.396466%. The notification was made in compliance with regulatory requirements.

    London Stock Exchange·
    US
    RNLXY
    0.00%
    US
    RNLXD
    0.00%
    London Stock Exchange·
    US
    RNLXY
    0.00%
    US
    RNLXD
    0.00%
    © 2026 Longbridge｜Disclaimer